A study published in the New England Journal of Medicine on Wednesday showed that hydroxychloroquine had no significant effect in preventing infection with novel Coronavirus.
In the report, U.S. and Canadian researchers said 821 volunteers in both countries participated in the randomized, double-blind controlled trial.
These volunteers ranged in age from 33 to 50 and most of them were at high risk of novel Coronavirus infection.
Some volunteers have family members who have been diagnosed, while others work in medical care and first aid.
None of them had the symptoms of novel Coronavirus infection when they participated in the trial.
The volunteers were randomly assigned to either a treatment group receiving hydroxychloroquine or a control group receiving the same amount of a placebo.
The results showed that novel Coronavirus infection was 11.8% in the treatment group and 14.3% in the control group during the trial.
The researchers don’t think this is a statistically significant difference.
In terms of side effects, nausea, diarrhea and abdominal discomfort were reported in 40.1% of the treatment group, a higher proportion than in the control group.
But there were no serious adverse reactions or cardiac complications.
The goal of the study was to see if hydroxychloroquine could help prevent a novel Coronavirus infection, said David Bolwell, Professor at the University of Minnesota School of Medicine and one of the lead researchers.
Hydroxychloroquine was considered one of the potentially effective drugs after the coVID-19 outbreak.
However, recent studies on hydroxychloroquine have been controversial, with some places abandoning the use of hydroxychloroquine in patients with COVID-19.
The role of hydroxychloroquine is still being studied and discussed in international academic circles. Some research projects are aimed at exploring whether hydroxychloroquine can help prevent mild patients from developing into severe ones.